Zoetis Inc. Overview
Pro stress-test →Zoetis Inc. is the global leader in animal health, developing medicines, vaccines, diagnostics, and technologies for companion animals and livestock. With a diversified portfolio spanning 68% companion animals (dogs, cats, horses) and 31% livestock (cattle, swine, poultry, fish, sheep), the company serves veterinarians, livestock producers, and pet owners worldwide.
Strategic Profile
Pro stress-test →Zoetis employs a "Continuum of Care" strategy—Predict, Prevent, Detect, and Treat—to capture revenue across an animal's entire lifecycle through genetic testing, vaccines, diagnostics, and therapeutics. The company maintains a dominant market position fortified by strong R&D innovation, with a 12-candidate blockbuster pipeline targeting high-value therapeutic areas including chronic kidney disease and oncology.
Competitive Landscape
Pro stress-test →Zoetis competes against IDEXX Laboratories in diagnostics and companion animal care, and Elanco Animal Health in livestock and parasiticides. The company differentiates through its comprehensive portfolio spanning species and channels, plus superior R&D pipeline depth. While Elanco faces pricing headwinds, Zoetis maintains premium positioning supported by 72% gross margins and innovation velocity.
Industry Context
Zoetis Inc. operates in Animal Health / Veterinary Pharmaceuticals & Biologics.
Key facts
Founded: 1950 · Headquarters: Parsippany, New Jersey, US · Revenue: $9.5B · Market cap: $56.8B